Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 9,367 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: minocycline; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years to 85 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 30
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 25 more

Conditions: Acute Lymphoblastic Leukemia/Lymphoma, Myelodysplasia, Acute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Chronic Myelogenous Leukemia
Interventions: Not listed
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Up to 22 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 32
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Parkinson Disease
Interventions: Procedure/Surgery: Biofluid samplings; Procedure
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research; Other
Eligibility: 30 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Portland, Oregon + 2 more

Conditions: Non-Small Cell Lung Carcinoma
Interventions: SGN-15, Docetaxel; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Portland, Oregon

Conditions: Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions: Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical); Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 62
States / cities: Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more

Conditions: Asthma
Interventions: 80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg, 40 μg budesonide HFA pMDI, placebo HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Huntington, California • Long Beach, California • Mission Viejo, California + 17 more

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 45
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions: SAR443579; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more

Conditions: Allergic Rhinitis Due to Grass Pollens
Interventions: 300 IR, Placebo; Drug
Lead sponsor: Stallergenes Greer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more

Conditions: Endothelial Dysfunction
Interventions: Centella Asiatica, Placebo Comparator; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 50 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Triple-Negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 93
States / cities: Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more

Conditions: Endogenous Cushing's Syndrome
Interventions: Levoketoconazole, Placebo; Drug
Lead sponsor: Cortendo AB; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Atlanta, Georgia + 7 more

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions: Urelumab (BMS-663513); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Elevated Lipoprotein(a), Cardiovascular Disease
Interventions: ISIS 681257, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more

Conditions: Myelodysplastic Syndromes (MDS)
Interventions: venetoclax, azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more

Conditions: Leiomyoma
Interventions: BAY1002670, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo, Background PAH Therapy; Biological · Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions: cabozantinib, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Interventions: CAB-ROR2-ADC, PD-1 inhibitor; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 30 more

Conditions: Parkinson's Disease
Interventions: Exercise and Education for Parkinson's Disease; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Aortic Stenosis
Interventions: Medtronic TAV, Edwards TAV; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Distal Subungual Onychomycosis
Interventions: TMI-358, MMI-467; Drug
Lead sponsor: Talima Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 7
States / cities: Tucson, Arizona • San Diego, California • Miami, Florida + 4 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Bortezomib, Iberdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 43
States / cities: Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more

Search by objective public record fields.

Minocycline to Treat Amyotrophic Lateral Sclerosis

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)

FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Centella Asiatica in Older Adults

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)